HCG Q4 FY26 Results Date: Key Details for May 2026

Results event: what HCG has scheduled

HealthCare Global Enterprises Ltd (HCG) has lined up its Q4 and full-year FY26 financial results event for May 20, 2026. The company said it will discuss audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Ahead of the discussion, the audited results are slated to be approved by the Board of Directors on May 19, 2026. For investors, the timing matters because the filing will bring audited numbers for the full year and clarity on segment performance across HCG’s network.

Board meeting and reporting scope

The May 19 board meeting is positioned as the formal approval point for both standalone and consolidated audited statements for Q4 and FY26. The subsequent May 20 discussion is expected to focus on the audited outcome for the quarter ended March 31, 2026, and the full-year print. HCG’s earlier updates referenced both standalone and consolidated performance, which makes the audited set important for reconciling operational commentary with final reported numbers. The company’s listed identifiers referenced in earlier disclosures include BSE: 539787 and NSE: HCG.

HCG’s operating footprint: oncology and fertility

HCG describes itself as India’s largest cancer care provider, operating 25 hospitals across India and Africa. Alongside oncology, it also operates in fertility care under the ‘Milann’ brand. This mix means consolidated numbers can reflect both the core oncology network and the fertility business, while some disclosures also discuss metrics excluding Milann. Investors typically track the relationship between centre maturity, volumes, and margins when a hospital network reports growth.

Latest disclosed quarter trend: Q3 FY26 snapshot

For Q3 FY26, HCG reported revenue of ₹633 crore, up 13.4% year-on-year. Adjusted EBITDA for the quarter was ₹111 crore, up 20% year-on-year, with adjusted EBITDA margin expanding to 17.5%. The company also reported patient volume growth of 8% year-on-year and an ARPP of around ₹84,000, up 5%. It additionally reported that digital revenue grew 26% year-on-year.

Nine-month FY26 context from earlier release

In another disclosure for the same period, HCG reported Q3 FY26 consolidated revenue of ₹633.1 crore (₹6,331 million), up 13% year-on-year from ₹558.6 crore (₹5,586 million). For the nine months of FY26, consolidated revenue was reported at ₹1,893.1 crore (₹18,931 million), up 16% year-on-year from ₹1,637.7 crore (₹16,377 million). These figures provide context for how the year has progressed into the March-ending quarter that will be audited and finalised in the Q4 and FY26 release.

Q2 FY26 reference point: profitability swing and balance sheet

For Q2 FY26, HCG reported consolidated revenue of ₹615.16 crore (₹61,516 lakhs), up 11.3% year-on-year and marginally up quarter-on-quarter. Consolidated profit after tax was ₹18.56 crore (₹1,856 lakhs) in Q2 FY26 versus a loss of ₹74.30 crore (₹7,430 lakhs) in Q1 FY26, as per the same set of metrics. On a standalone basis, Q2 FY26 revenue was ₹343.41 crore (₹34,341 lakhs) with profit after tax at ₹14.77 crore (₹1,477 lakhs). Standalone EPS for Q2 FY26 was disclosed as basic ₹1.07 and diluted ₹0.77.

Cash flows and leverage indicators disclosed for H1 FY26

HCG reported positive operating cash flow of ₹192 crore for H1 FY26. It also reported investing cash outflow of ₹58 crore and financing cash outflow of ₹189 crore for the same period. As of September 30, 2025, consolidated total assets were reported at ₹3,585.60 crore (₹358,560 lakhs) and consolidated borrowings at ₹798.95 crore (₹79,895 lakhs). Consolidated cash and cash equivalents were reported at ₹182.01 crore (₹18,201 lakhs). These disclosures set the baseline for what investors may compare against the audited FY26 closing position.

FY25 comparator: Q4 performance and operating metrics

For Q4 FY25 (quarter ended March 31, 2025), HCG reported consolidated revenue of ₹585.1 crore (₹5,851 million), up 18% year-on-year from ₹494.6 crore (₹4,946 million). Adjusted EBITDA was reported at ₹107.0 crore (₹1,070 million) versus ₹94.1 crore (₹941 million) a year earlier, a 14% year-on-year increase, while reported EBITDA was ₹105.7 crore (₹1,057 million). Consolidated PAT after taxes and minority interest for Q4 FY25 was ₹7.4 crore (₹74 million), compared with ₹21.3 crore (₹213 million) in the corresponding quarter of the previous year. Operationally, the company disclosed ARPOB of ₹44,236 and overall AOR of 67.0% for Q4 FY25, and it noted the addition of two LINACs at Vizag and Nagpur and one PET CT in Africa.

Key facts at a glance

Market impact: what investors can verify from the audited print

The Q4 and FY26 audited filing will allow investors to validate whether margin expansion seen in Q3 FY26 (17.5% adjusted EBITDA margin) sustained into the March quarter. It will also put audited numbers against earlier disclosures for volumes, ARPP (around ₹84,000 in Q3 FY26), and digital revenue growth (26% year-on-year in Q3 FY26). With earlier H1 FY26 disclosures showing financing outflows and borrowings, the audited FY26 statements can help readers compare period-end cash, debt, and cash flow movement on a like-for-like basis. Separately, FY25 disclosures provide an operating benchmark for Q4 seasonality, including AOR and ARPOB, which are often tracked in hospital businesses.

Why the May 19 to May 20 sequence matters

A board-approved audited set on May 19, followed by a May 20 discussion, creates a clear timeline for the market to receive finalised information. It also reduces ambiguity that can exist between unaudited quarterly updates and audited annual statements, especially when a company reports both standalone and consolidated numbers. For HCG, which operates across oncology centres and the Milann fertility brand, audited disclosures help stakeholders compare the group view with business-level commentary previously shared.

Conclusion

HCG’s Q4 and FY26 results are scheduled for discussion on May 20, 2026, after board approval of audited standalone and consolidated financials on May 19. The audited release will be read alongside recent disclosures that showed Q3 FY26 revenue of ₹633 crore with a 17.5% adjusted EBITDA margin, and Q2 FY26 consolidated revenue of ₹615.16 crore with positive PAT. Investors will also look for updated audited cash flow and balance sheet positions versus the H1 FY26 disclosures, and for operational continuity across the company’s oncology and fertility footprint.